No headlines found.
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Business Wire (Tue, 31-Mar 4:05 PM ET)
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Business Wire (Tue, 24-Mar 8:00 AM ET)
Business Wire (Tue, 17-Feb 8:00 AM ET)
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Business Wire (Mon, 9-Feb 8:00 AM ET)
Business Wire (Mon, 12-Jan 8:05 AM ET)
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Turn Therapeutics trades on the NASDAQ stock market under the symbol TTRX.
As of April 2, 2026, TTRX stock price climbed to $3.35 with 38,790 million shares trading.
TTRX has a beta of -0.35, meaning it tends to be less sensitive to market movements. TTRX has a correlation of 0.00 to the broad based SPY ETF.
TTRX has a market cap of $98.64 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that TTRX belongs to (by Net Assets): VTI.
TTRX support price is $2.96 and resistance is $3.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TTRX shares will trade within this expected range on the day.
